Form 4 for RPRX Royalty Pharma plc
Accepted 2026-05-08 17:10:50 ET · period of report 2026-05-06 · accession 0001838139-26-000014 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-08 17:10 | 2026-05-06 | RPRX | Urist Marshall | EVP, Research, Investments | A - Grant | $0.00 | +18.2K | 45.6K | +66% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Ordinary Shares | 2026-05-06 | A | A | 18,197 | $0.00 | 45,565 | D | — | — | (F1) Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards. |